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ABSTRACT 
Objective: Innovative enhancement of therapeutic window of Metformin hydrochloride (MFH) and bioavailability through mucoadhesive 
microspheres by polymeric inculcation of hydroxypropyl methylcellulose K4M grade (HPMC K4M), hydroxypropyl methylcellulose K100M grade 
(HPMC K100M) and Kollidon SR grade (KS).  
Methods: Controlled release system was developed by incorporating semi-synthetic and synthetic polymers by modified solvent evaporation 
technique. Fabrication of mucoadhesive microspheres was designed by the implementation of experimental designs to obtain most optimum 
concentration of selected factors. The method was optimized by Box Behnken design (BBD) with selected factors as concentrations of semi-
synthetic and synthetic polymer with stirring speed influence for the obtained responses that were mean particle size (Y1) entrapment efficiency of 
drug (Y2) and percent mucoadhesion (Y3). Microspheres were characterized for particle size, entrapment efficiency of drug, ex-vivo mucoadhesion 
study, in vitro study, Fourier transform infrared spectroscopy (FTIR), x-ray diffraction (XRD) detection and H1 Nuclear magnetic resonance (NMR) 
quantification for optimized formulation. 
Results: Implementation of response surface method software for BBD yielded stable microspheres with mean particle size 274 µm, entrapment 
efficiency of drug 85.07% and percent mucoadhesion 67.03% for optimized formulation F5. 
Conclusion: Bridging of MFH with the highly innovative combination of semi-synthetic and synthetic polymers yielded stable, cost-effective 
microspheres with improved bioavailability with controlled-release effect as till date no literature is available that provide information with 
selected polymeric combination and analytical characterization.  
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INTRODUCTION 
Selection of drug is the most optimum parameter in designing of a 
particular dosage form. In our research, we had focused on such a 
drug that has multivariate effect with minimum side effects. MFH 
was selected as a model drug in present research work. MFH is the 
most felicitously picked alternative in treatment of non-insulin 
dependent diabetes mellitus (NIDDM. It is an orally administered, 
anti-hyperglycemic biguanide drug [1-4]. MFH has numerous other 
applications in drug therapy including emendation of menstrual 
cycles by making them more regular and enhances fertility in 
women. It is also used in patients with polycystic ovarian syndrome 
(PCOS) [5, 6]. It has anti-tumor effect on colon, ovaries, pancreas, 
breast and lungs cancer cells, hence, it has strong anti-proliferative 
effect [7], possesses anti-oxidant activity, shows high efficacy in 
diabetic nephropathy [8]. Several research articles revealed that 
MFH also exhibits good cardiovascular protective effect that was 
independent of its glucose lowering efficacy [9, 10]. There are some 
minor side effects including stomach pain, nausea, vomiting, 
diarrhea, muscle pain with major adverse effect includes 
ketoacidosis, hence the drug should be prohibited to patients with 
impaired kidney functioning due to occurrence of lactic acid 
acidosis, and otherwise it is the first line treatment drug in patients 
associated with diabetes mellitus either alone or in combination 
with other glucose-lowering drugs [11]. MHF is a biguanide white to 
off-white compound having molecular weight 165.63 and molecular 
formula C4H11N5 · HCl (Imido dicarbo nimidic diamide, N, N-
dimethyl-,monohydrochloride; 1,1-Dimethylbiguanide mono hydro 
chloride) with absolute bioavailability of 50-60% and plasma half-
life of 1.5 h to 4.5 h, the therapeutic window of MFH in plasma lies 
between 01 and 50 µM [12]. On oral administration, there exists an 
incomplete gastrointestinal absorption of MFH with absolute 
bioavailability of 40 to 60 % and rapid elimination, hence the 
administration of a controlled release (CR) formulation of MFH 
would be beneficial to maintain the optimum therapeutic window of 
drug and minimize dosing frequency due to short half-life so 
enhanced patient acceptability will be obtained [13]. In this research 
we had tried to develop a polymeric inculcation of semi-synthetic 
and synthetic polymers for CR of MFH by microspheres fabrication. 
The semi-synthetic polymer selected was HPMC, also known as 
hypromellose, it is one of the best known semi-synthetic non-ionic 
cellulosic, biocompatible and viscoelastic polymer with unique 
property of high water absorption and retention capacity. There 
were several grades of hypromellose available, the composition 
differs due the substitution of methyl and hydroxyl propyl group 
present in the structure [14]. The selected HPMC grades in our 
research comprised of HPMC K4M and HPMC K100M as synthetic 
polymers in fabrication of CR formulation of MFH. The combination 
of both grades had been opted as they yielded high swellability, as 
soon as they encounters with water or simulated gastric fluid they 
develop a viscous gel layer and results in CR of drug from HPMC 
matrices. HPMC K4M has strong mucoadhesive property whereas 
HPMC K100M has high gastro-retentive nature [15, 16]. The another 
desirably chosen polymer for our research was KS, it comes under 
the category of synthetic polymer, the sustaining capacity of drug in 
matrix formulation makes KS an ideal candidate in fabrication of CR 
formulations along with improved bioavailability [17, 18]. As our 
focus in this research was to enhance the therapeutic window of 
MFH through incorporating the drug with semi-synthetic and 
synthetic polymeric inculcations of matrix yielding CR of drug, we 
tried to design mucoadhesive microspheres of MFH to increase the 
residence time of formulation in the stomach. The narrow 
therapeutic window and short half-life of MFH make it a suitable 
candidate to be designed as mucoadhesive microspheres for 
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enhancement of therapeutic index, improved bioavailability and 
reduced side effects [19]. The interpenetration of polymer molecules 
to mucosal membrane was higher with low molecular weight 
polymers whereas with higher molecular weight entanglement will 
be obtained, hence a combination of low and high molecular weight 
polymers were selected to obtain improved effect [20, 21]. So, in our 
research we had selected different grades of HPMC as opted semi-
synthetic polymer to obtain good mucoadhesive, gastro-retentive 
(GR) and CR effect along with enhanced CR effect of KS as the 
synthetic polymer for fabrication of MFH loaded mucoadhesive 
microspheres. Literature revealed numerous research and review 
articles on MFH, in one study performed by Karna S et al., 2016, they 
had prepared GR, swellable and floating sustained release tablets. 
They had fabricated the tablet formulation by incorporating HPMC, 
xanthan gum, sodium alginate, carbopol and ethyl cellulose. The 
prepared formulation was also found to be stable for tenure of three 
months [22]. The study conducted by Quazi M A et al., 2020, 
revealed formulation of MFH loaded microspheres comprising of 
natural and synthetic polymer for comparative analysis. The result 
revealed enhanced flow properties with higher drug entrapment 
efficiency for microspheres fabricated with synthetic polymer 
Carbopol as compared with formulation designed with natural 
polymer sodium alginate [23]. The present research study involved 
fabrication and characterization of MFH microspheres inculcating 
semi-synthetic and synthetic polymers by employing response 
surface methodology and implementing Box-Behnken design (BBD). 
BBD was selected from the ocean of various available experimental 
designs and applied to statistically optimize the formulation to 
improve therapeutic index and bioavailability of drug by 
enhancement of entrapment efficiency and CR of MFH in this study. 
The selected variables were HPMC K4M concentration (A), HPMC 
K100M concentration (B) Kollidon SR concentration (C) and stirring 
speed (D) along with selected response variables as mean particle 
size (Y1) percent entrapment efficiency (Y2) and percent 
mucoadhesion (Y3) of fabricated microspheres with predetermined 
level values for these variables estimated by trails according to 
factorial design [24, 25]. The selected method is highly innovative, 
especially the optimization of formulation parameters by following 
response surface method as till date there does not exists any 
literature reporting mucoadhesive microspheres of MFH with 
combination of HPMC K4M, HPMC K100M and KS fabricated by 
modified solvent evaporation technique. This makes our research 
work highly novel and discrete from the available literature with 
characterization of optimized formulation by latest modern 
analytical techniques incorporating estimation of particle size, 
entrapment efficiency of drug, percentage mucoadhesion, in vitro 
drug release profile, drug polymer interaction analysis by FTIR, 
physical state estimation of drug by XRD detection and NMR based 
quantification.  
MATERIALS AND METHODS 
Chemicals and reagents  
Metformin hydrochloride was obtained as a gift sample from 
Aurobindo Pharmaceuticals Ltd, Hyderabad, India, HPMC K4M and 
HPMC K 100M were received from S D fine chemicals, Mumbai, 
India, Kollidon SR was purchased from Natco, Hyderabad, India, All 
other chemicals used were of analytical grade reagent. 
Method of fabrication 
Fabrication of MFH loaded microspheres comprising of semi-
synthetic and synthetic polymers were produced by 
contemporaneous application of solvent evaporation and diffusion 
techniques. Initially, as per the data obtained from RSM software by 
using BBD, the specified parameters were recorded and employed in 
microspheres formulation for seven batches from F1 to F7 by 
following ED. Initially, accurately weighed quantities of MFH, HPMC 
K4M, HPMC K100M, KS and 0.1% polyethylene glycol were mixed in 
1:1 mixture of dichloromethane and ethanol at room temperature. 
Then the above mentioned slurry was slowly introduced to 80 ml of 
0.46% (W/V) polyvinyl alcohol (emulsifier). The system was stirred 
for three hours by using Remi Lab Magnetic stirrer with speed meter 
to remove the volatile solvent ethanol at room temperature to 
produce spherical microspheres. The microspheres were collected 
by vacuum filtration and washed repeatedly with water. Finally, the 
prepared microspheres were dried at ambient temperature (25 °C) 
for 24 h and dried in vacuum chamber at 25 °C for 2 h to remove any 
residual solvent. All the process variables like concentration of 
HPMC K4M, concentration of HPMC K100M, concentration of KS and 
stirring speed were studied during optimization of microspheres 
and the most optimum concentration with maximum stabilized 
formulation was recorded as seen in table 2.  
Experimental design (ED) 
The present research of formulating and characterizing CR 
microspheres of MFH was mainly focused to improve the 
therapeutic index of drug by improving bioavailability and residence 
time of drug within body, as it is drug candidate that comes under 
the category of comprising low therapeutic window. Design and 
fabrication was statistically optimized by BBD for various 
formulation parameters like, maximum drug entrapment efficiency 
of microspheres and mean particle size. This research was executed 
by optimization of MFH microspheres through response surface 
methodology by applying BBD and using Design Expert 12.0.7.0 
software (STATEASE Inc., USA), with quadratic design model that 
yielded 27 experimental runs for present data [26, 27].  
Characterization of MFH loaded mucoadhesive microspheres 
through semi-synthetic and synthetic polymers 
Particle size estimation 
MFH loaded microspheres were accurately determined by optical 
microscopic method using calibrated stage micrometer.  
Entrapment efficiency of drug 
The quantity of pure MFH loaded in fabricated microspheres was 
investigated by taking 100 mg of prepared formulation in 50 ml of 
phosphate buffer (pH= 7.4) in volumetric flask then kept on 
sonicator at 125 W (Imeco sonofier, Imco ultrasonics, India) for two 
hours to mix uniformly, finally the volume was made up to 100 ml by 
adding buffer, then again this flask was kept on sonicator for one 
hour and kept as it is overnight for extraction of drug from 
microspheres. Then the solution was passed through 0.45 µm 
membrane filter to collect the filtrate. The respective dilutions were 
made from this stock solution and absorbance was measured at 233 
nm employing UV-visible spectrophotometer (UV-2450 Shimadzu, 
Japan) against blank. The method was repeated three times.  
Ex-vivo mucoadhesive study 
The mucoadhesive property of fabricated MFH loaded microspheres 
were evaluated by taking freshly excised piece of goat stomach 
mucosa and then they were mounted on glass slides with the help of 
cyanoacrylate glue and 50 prepared microspheres were spread on 
the wet rinsed tissue specimen with 4 drops of 0.01N HCl and 
immediately the slides were hung to the arm of USP tablet 
disintegration test apparatus with the help of suitable support. Then 
the disintegration test machine was operated and the attached 
mucosal specimen was given regular up and down movement in the 
fluid comprising 800 ml 0.01N HCl (pH = 2.0) at 37±0.5 °C in one 
liter vessel capacity for various time interval up to 7 h. Then the 
apparatus was stopped and the number of adhered microspheres to 
the mucosal tissue were counted [28, 29].  
In vitro drug release analysis  
The release of MFH drug from the prepared microspheres was 
studied in 0.1N HCl at pH 1.2 and in phosphate buffer pH 7.4 (900 
ml) respectively using a USP six station dissolution (LAB DISSO 
2000) rate testing apparatus with a rotating paddle at 50 rpm and 
25 cm depth 20 by maintaining temperature of 37±0.5 °C. Sample of 
5 ml was withdrawn at various time intervals and subsequently 
diluted using pH 7.4 phosphate buffer. After suitable dilutions the 
absorbance was measured at 206 nm for 0.1N HCl and 233 nm for 
phosphate buffer, using UV-visible spectrophotometer (2450 
Shimadzu, Japan) against a blank. The withdrawn sample was 
filtered through Whatman grade 1 filter paper and diluted to 
estimate MFH at 233 nm through spectroscopy against blank 
solution. The quantity of drug was estimated through calibration 
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curve and release studies were performed in triplicate and the 
observed data represented in table 6. 
FTIR analysis 
The detection of any possible interaction between pure drug and 
optimized formulation of MFH loaded microspheres were scanned 
through FTIR spectra by using Perkin-Elmer FTIR (spectrum RX). 
XRD study 
XRD analysis was performed to determine the crystalline 
characteristic of drug and optimized fabricated microspheres by 
using X-ray diffractometer (Brucker Axs, 08 Advance) [30].  
NMR analysis 
The compatibility analysis of fabricated MFH microspheres with 
incorporated polymers was performed by using proton (H1)Nuclear 
magnetic resonance spectroscope (ECX 400 JOEL, Japan) working at 
500 MHz and 300 K with dimethy sulphoxide (DMSO-d6) as solvent 
for estimation of chemical shift in this experiment.  
RESULTS AND DISCUSSION 
The present statistically optimized and BBD assisted MFH loaded 
microspheres were fabricated by employing optimized parameters 
as represented in table 1 and table 2. The fabrication method was 
experimentally designed and the data obtained from design for 
factors A, B and C with their corresponding responses Y1, Y2 and Y3 
were explained through fig. 1 and fig. 2 with the corresponding 
values represented in table 1 and table 2. Finally, analysis of 
variance (ANOVA) was applied to obtain significant difference from 
design matrix and the data obtained after implementation of ANOVA 
was represented in table 3, table 4 and table 5 and were found to be 
significant. The data obtained from experimental design for factors 
A, B and C with their corresponding responses Y1, Y2 and Y3 were 
explained through fig. 1 and 2. 
Particle size analysis  
It was observed from the obtained data that mean particle size of MFH 
loaded microspheres ranged between 246.01±0.49 µm to 289.13±0.07 
µm for all fabricated formulations, whereas in one study executed by 
Kesharwani S et al., 2020 [31] they had fabricated MFH microspheres 
incorporating eudragit and HPMC with particle size range 397±23.22 
µm to 595±15.82 µm and entrapment efficiency ranged from 
(83.49±1.33) % to (60.02±1.65) %. On implementation of BBD to the 
parameter mean particle size yielded superior microspheres with 
spherical surface, smaller particle size and microsphere size increased 
on increasing polymer concentration for all the seven formulations. 
The mean particle size of 274 µm for F5 formulation was obtained 
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Table 1: Data representing optimized fabrication parameters and investigated range during microspheres formulation  
Factor Name Units Minimum Maximum  Low level  High level Mean Standard deviation  
 A Concentration of HPMC K4M  mg 102.00 106.00 -1 ↔ 102.00 +1 ↔ 106.00 104.00 01.35 
 B Concentration of HPMC K100M mg 110.00 150.00 -1 ↔ 110.00 +1 ↔ 150.00 130.00 13.58 
 C Concentration of KS mg 020.00 40.00 -1 ↔ 20.00 +1 ↔ 40.00 030.00 06.79 
 D Stirring speed rpm 600.00 1200.00 -1 ↔ 600.00 +1 ↔ 1200.00 900.00 203.81 
*mean±SD (Standard deviation), n=3 
 
Table 2: Data representing Box-Behnken experimental design layout with selected factors and obtained responses 
Std Run Factor 1 Factor 2 Factor 3 Factor 4 Response Y1 Response Y2 Response Y3 
4 1 106 150 30 900 279 85.73 64.08 
10 2 106 130  30 600 283 83.65 64.31 
25 3 104 130  30 900 272 84.97 67.58 
23 4 104 110 30 1200 248 73.94 61.39 
9 5 102 130  30 600 267 78.04 65.27 
16 6 104 150  40 900 288 85.03 63.06 
14 7 104 150  20 900 281 84.93 64.71 
27 8 104  130 30 900 272 84.97 67.58 
1 9 102  110 30 900 259 69.87 65.28 
15 10 104 110 40 900 266 72.07 64.15 
17 11  102 130 20 900 263 75.38 63.74 
24 12 104 150 30 1200 264 85.97 64.03 
3 13 102 150 30 900 271 84.08 64.61 
12 14 106 130 30 1200 279 83.85 65.04 
11 15 102 130 30 1200 258 77.43 64.91 
19 16  102 130 40 900 263 79.08 65.52 
13 17 104 110 20 900 257 72.94 62.47 
26 18 104 130 30 900 272 84.97 67.58 
2 19 106 110 30 900 274 83.06 64.72 
22 20 104 150 30 600 284 85.02 65.53 
8 21 104 130 40 1200 279 85.07 66.17 
5 22 104 130 20 600 283 83.09 64.72 
18 23 106 130 20 900 280 81.85 63.94 
21 24 104 110 30 600 265 77.03 64.21 
6 25 104 130 40 600 287 85.04 66.32 
7 26  104 130 20 1200 261 82.41 62.83 
20 27 106 130 40 900 287 84.67 67.03 
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Table 3: ANOVA data for quadratic model representing response Y1 (mean particle size) 
Source Sum of squares Df Mean square F value p value Prob>F 
Model 2435.50 10 243.55 6.75 0.0004  
Significant 
 
A-Concentration of HPMC K4M (mg) 850.08 1 850.08 23.57 0.0002 
B-Concentration of HPMCK100M(mg) 800.33 1 800.33 22.19 0.0002 
C-Concentration of Kollidon SR(mg) 168.75 1 168.75 4.68 0.0460 
D-Stirring speed(rpm) 533.33 1 533.33 14.78 0.0014 
AB 12.25 1 12.25 0.34 0.5682 
AC 12.25 1 12.25 0.34 0.5682 
AD 6.25 1 6.25 0.17 0.6828 
BC 1.00 1 1.00 0.028 0.8699 
BD 2.25 1 2.25 0.062 0.8060 
CD 49.00 1 49.00 1.36 0.2609 
  
Entrapment efficiency of drug 
The RSM assisted and ED implemented yielded high entrapment of 
drug in fabricated microspheres corresponding to the following data 
ranging from (68.04±0.07) % to (85.98±0.01) % for all the 
formulation from F1 to F7. It was observed that on increase in 
polymer concentration, the entrapment efficiency of formulation 
also increased due to higher inculcations with increased polymer 
concentration and enhanced stirring speed. In present 
experimentally designed method by BBD, the two selected response 
were mean particle size and drug entrapment efficiency, so on 
implementation of selected model for both responses yielded 
maximum optimized drug entrapment efficiency as 85.07% for F5 
formulation with maximum optimization. 
 
Table 4: ANOVA data for quadratic model representing response Y2 (entrapment efficiency) 
Source Sum of squares Df Mean square F value p value Prob>F 
Model 492.97 10 49.30 6.54 0.0005 Significant 
 A-Concentration of HPMC K4M (mg) 126.30 1 126.30 16.75 0.0008 
B-Concentration of HPMCK100M(mg) 318.79 1 318.79 42.29 <0.0001 
C-Concentration of Kollidon SR(mg) 8.94 1 8.94 1.19 0.2922 
D-Stirring speed(rpm) 0.85 1 0.85 0.11 0.7409 
AB 33.29 1 33.29 4.42 0.0518 
AC 0.19 1 0.19 0.026 0.8747 
AD 0.16 1 0.16 0.022 0.8846 
BC 0.24 1 0.24 0.031 0.8620 
BD 4.08 1 4.08 0.54 0.4726 
CD 0.13 1 0.13 0.017 0.8987  
 
Ex-vivo mucoadhesive study 
It was observed that as the concentration of mucoadhesive polymers 
was increased, there was gradual increase in degree of 
mucoadhesion to the mucosal sample tissue, but with increase in 
stirring speed the mucoadhesive tendency was reduced. Hence less 
stirring speed with higher concentration of semi-synthetic polymers 
yielded enhanced mucoadhesion. The values obtained ranged from 
(60.09±0.03) % to (68.07±0.05) % for all the formulation from F1 to 
F7 with 67.03% for most optimized formulation F5. 
  
Table 5: ANOVA data for quadratic model representing response Y3 (percent mucoadhesion) 
Source Sum of squares Df Mean square F value p value Prob>F 
Model 48.97 14 3.50 3.25 0.0237 Significant 
 A-Concentration of HPMC K4M (mg) 3.675E-003 1 3.675E-003 3.418E-003 0.9543 
B-Concentration of HPMCK100M(mg) 1.20 1 1.20 1.12 0.3110 
C-Concentration of Kollidon SR(mg) 8.07 1 8.07 7.50 0.0180 
D-Stirring speed(rpm) 2.99 1 2.99 2.78 0.1213 
AB 2.250E-004 1 2.250E-004 2.092E-004 0.9887 
AC 0.43 1 0.43 0.40 0.5395 
AD 0.30 1 0.30 0.28 0.6088 
BC 2.77 1 2.77 2.58 0.1343 
BD 0.44 1 0.44 0.41 0.5364 
CD 0.76 1 0.76 0.70 0.4179  
A2 5.18 1 5.18 4.82 0.0486  
B2 27.28 1 27.28 25.37 0.0003  
C2 11.36 1 11.36 10.56 0.0070  
D2 11.22 1 11.22 10.43 0.0072  
 
In vitro drug release analysis 
The experimentally designed and optimized MFH microspheres 
were prepared by modified solvent-evaporation technique by 
incorporating semi-synthetic and synthetic polymers. The 
representation of drug release behavior of MFH fabricated 
microspheres revealed that all preparations from F1 to F7 were able 
to control the drug release from 04 to 10 h with percent drug release 
ranging from 96.08% to 91.76% respectively. F5 preparation 
exhibited 92.81% release profile after duration of 10 h, hence it was 
selected as optimized formulation. In one study conducted by It was 
observed that on increasing the concentration of HPMC K100M and 
synthetic polymer KS, release was decreased. From among all seven 
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preparations, F5 was selected as most optimized preparation 
representing better drug release with enhanced bioavailability. 
Identification of best fitting models was performed by using 
coefficient of determination (R2) by placing the data of drug release 
kinetics. It was observed that for the formulation from F1 to F7 
reached greater values for coefficient of determination (R2) ranging 
from 0.928 to 0.983 for zero order and release exponent value (n) 
varied from 1.502 to 2.052. The observed data of Korsmeyer-Peppas 
model recommended non-Fickian diffusion mechanism for 
fabricated MFH microspheres can be seen from table 6. 
 
Table 6: Drug release profile for MFH loaded microspheres by incorporating semi-synthetic and synthetic polymers 
Formulation code Correlation coefficient (R2) Release exponent (n) 
 Zero order First order Higuchi model Korsmeyer model  
F1 0.928 0.736 0.718 0.817 1.502 
F2 0.940 0.769 0.825 0.952 1.564 
F3 0.931 0.878 0.839 0.840 1.731 
F4 0.955 0.926 0.856 0.863 1.908 
F5 0.979 0.952 0.898 0.942 2.052 
F6 0.973 0.959 0.921 0.949 2.019 
F7 0.983 0.968 0.941 0.957 1.977 
 
FTIR study 
The FTIR analysis was performed by taking samples of pure drug 
and optimized formulation comprising of semi-synthetic and 
synthetic polymers inculcation. It was observed from the obtained 
spectra that no interaction was present between drug and polymers 
as no additional peaks were observed, representing stable nature of 
MFH in formulation, as seen in fig. 3. 
 
 
Fig. 3: IR spectra of metformin hydrochloride API (a) Metformin hydrochloride formulations (b) 
 
XRD study  
The XRD data reveals the physical state of pure MFH by showing 
sharp peak, representing its crystalline nature, whereas broad peaks 
were obtained for polymers representing their amorphous form. 
The results of diffractogram showed no variation in representative 
peak intensity height between pure MFH and the optimized 
formulation F5, exhibiting its crystalline nature. The observed data 
can be correlated with fig. 4.  
NMR analysis  
The H1NMR spectra obtained for optimized MFH fabricated 
microspheres yielded sharp singlet at 2.92 ppm corresponding to 
two equivalent methyl groups, this sharp, isolated singlet was 
chosen as an essential criterion for quantitative determination of 
MFH. At 6.71 ppm one more singlet was observed due to remaining 
four protons (2 H from–NH and 2H from–NH2), another prominent 
signal at 7.20 ppm was due to the concurrent effect of two protons, 
one from–NH group and anther from HCl, respectively. The signals 
obtained at 2.49 ppm and 3.32 ppm were due to presence of residual 
solvent and water of solvent from DMSO-d6, respectively. The 
detailed NMR spectrum of fabricated formulation can be correlated 
to fig. 5 and it represented that all essential chemical shifts of MFH 
were retained in the formulation, hence exhibiting no interaction 
between pure drug MFH and the selected semi-synthetic and 
synthetic polymers. 
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Fig. 4: XRD pattern of pure metformin hydrochloride and optimized formulation F5 
 
 
Fig. 5: NMR spectra of metformin hydrochloride API (a) Metformin hydrochloride formulations (b) 
 
CONCLUSION 
The BBD assisted optimized MFH loaded microspheres were found 
to have CR behavior with enhanced flow properties and improved 
bioavailability as compared with pure drug along with spherical 
microspheres fabrication with good drug entrapment efficiency and 
higher mucoadhesive tendency. The modified solvent evaporation 
technique being uncomplicated, yielded microspheres with 
improvement in the therapeutic window of drug with stable 
fabricated microspheres as observed from FTIR and H1 NMR 
analysis.  
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